Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. - According to the findings of this nonrandomized controlled trial, patients enjoy greater menopause-related quality of life after risk-reducing salpingectomy (RRS) than after risk-reducing salpingo-oophorectomy (RRSO), independent of hormone replacement treatment.

• An international follow-up study is currently being conducted to assess the oncologic safety of this therapy.

• In total, 577 women (mean [SD] age, 37.2 [3.5] years) were recruited: 297 (51.5%) were pathogenic BRCA1 variant carriers and 280 (48.5%) were BRCA2 pathogenic variant carriers.

• Three hundred ninety-four individuals had received RRS and 154 had received RRSO at the time of analysis.

• The adjusted mean increase from baseline on the Greene Climacteric Scale during 1 year after RRSO was 6.7 points higher than after RRS without hormone replacement therapy.

• In comparison to RRS, the difference after RRSO with hormone replacement therapy was 3.6 points.